In a recent release, the US Food and Drug Administration (US FDA) has extended the approval of a hybrid closed-loop diabetes management device to include individuals within the age of 7 to 13 and with type 1 diabetes. The device is intended to automatically monitor glucose and provide a suitable dose of insulin with minimal inputs from the user.
Challenges faced by Pediatric patients with type 1 diabetes: Continuous and Life-long management Round the clock glucose monitoring Uneven Sleep pattern due to periodic glucose monitoring & management Working of the Insulin Delivery System The approval of the insulin monitoring and delivery system is expected to improve the quality of life for vulnerable population with chronic conditions, like pediatric patients with juvenile diabetes. Key Features ·Glucose levels in the body are measured every five minutes through a sensor attached to the body…
